AzTrials
AzTrials

Cortico-cortical Paired Associative StimulationNCT07431749

The Use of Dual-coil Transcranial Magnetic Stimulation to Measure and Modulate Poststroke Interhemispheric Inhibition.

A study testing Dual coil transcranial magnetic stimulation in people with Cortico-cortical Paired Associative Stimulation, run by The Hong Kong Polytechnic University at 2 sites in Hong Kong.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Objectives: This project will (1) establish the test-retest reliability of a novel transcranial magnetic stimulation-electroencephalography (TMS-EEG) interhemispheric inhibition (IHI) measure and (2) validate it against the TMS-EMG-based IHI measure (the gold standard). Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
What is being tested?
Dual coil transcranial magnetic stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
2 sitesHong Kong
Study dates
15 Jul 2026to 1 Jun 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • (1) have a diagnosis of ischemic or hemorrhagic stroke, with time after stroke onset≥6 months. For stroke patients, we will invite participants to receive a structural magnetic resonance imaging (MRI) at the University Research Facility in Behavioral and Systems Neuroscience to verify their actual lesion location; (2) aged between 18 and 80 years old; (3) with residual upper limb functions from 4-7 levels in the Functional Test for the Hemiplegic Upper Extremity (Hong Kong version); (4) have evocable MEP from both M1; (5) able to give informed written consent to participate in the study. (6) able to understand and communicate with Chinese.

Who cannot join

  • any contraindications to TMS (screened by the safety checklist by Rossi); (2) any concomitant neurological disease; (3) any sign of moderate-to-severe cognitive problems, i.e., the abbreviated mental test Hong Kong version<6 out of 10 points [22]; and (4) Modified Ashworth score>2 in hand, wrist or elbow extensor muscle in their hemiparetic upper limbs.
  • In addition, a group of right-hand-dominant healthy adults, without any known neurological and psychiatric diseases, will be enrolled.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

JIAQI JACK Zhang, PhD contact

27666696

jack-jiaqi.zhang@polyu.edu.hk

Hong Kong2 sites, 2 recruiting
  • Hong Kong Polytechnic University

    Hong Kong

    Recruiting
  • The Hong Kong Polytechnic University

    Hong Kong

    JIAQI JACK Zhang, PhD, 27666696, jack-jiaqi.zhang@polyu.edu.hk

    Not yet recruiting

Other trials in Hong Kong

About this study

Official title: Using Dual-coil Transcranial Magnetic Stimulation to Measure and Modulate Poststroke Interhemispheric Inhibition (IHI): A Concurrent TMS-EEG-EMG Study

Objectives: This project will (1) establish the test-retest reliability of a novel transcranial magnetic stimulation-electroencephalography (TMS-EEG) interhemispheric inhibition (IHI) measure and (2) validate it against the TMS-EMG-based IHI measure (the gold standard). It will also (3) compare effects of dual-coil cortico-cortical paired associative stimulation (ccPAS) protocols with different interstimulus intervals (ISI) on this TMS-EEG-based IHI marker in poststroke patients. Methods: Study 1: IHI will be conducted in 20 stroke patients and 20 healthy counterparts using TMS-EEG and TMS-EMG; furthermore, both measures will be repeated after one week for test-retest reliability. Study 2: A randomized-crossover trial where 20 stroke patients undergo a single-session ccPAS in three separate visits (ISI: 8ms: LTD-like, 12ms: LTP-like, 100ms: sham) to investigate the differential modulatory effects in IHI.

Read the detailed description

Objectives: This project will (1) establish the test-retest reliability of a novel transcranial magnetic stimulation-electroencephalography (TMS-EEG) interhemispheric inhibition (IHI) measure and (2) validate it against the TMS-EMG-based IHI measure (the gold standard). It will also (3) compare effects of dual-coil cortico-cortical paired associative stimulation (ccPAS) protocols with different interstimulus intervals (ISI) on this TMS-EEG-based IHI marker in poststroke patients. Methods: Study 1: IHI will be conducted in 20 stroke patients and 20 healthy counterparts using TMS-EEG and TMS-EMG; furthermore, both measures will be repeated after one week for test-retest reliability. Study 2: A randomized-crossover trial where 20 stroke patients undergo a single-session ccPAS in three separate visits (ISI: 8ms: LTD-like, 12ms: LTP-like, 100ms: sham) to investigate the differential modulatory effects in IHI.

Being tested
Dual coil transcranial magnetic stimulation
Keywords
cortico-cortical paired associative stimulation, transcranial magnetic stimulation, stroke
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dual coil transcranial magnetic stimulationDevice

    The ccPAS will be applied using a MagPro X100/R30 stimulator and a MagPro R20/R30 extension connected to two vertically oriented figure-of-eight coils designed for bilateral hemispheric stimulation.

Study groups in NCT07431749
Study groupRoleWhat they receive
ccPAS (8ms)ExperimentalccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 8ms after the first pulse over the contralesional M1, during premovement stage.
Receives: Device: Dual coil transcranial magnetic stimulation
ccPAS (12ms)ExperimentalccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 12ms after the first pulse over the contralesional M1, during premovement stage.
Receives: Device: Dual coil transcranial magnetic stimulation
Sham ccPASSham comparatorccPAS session will involve 180 paired pulses repeated at a frequency of 0.2Hz (approximately 15 minutes), stimulating the ipsilesional M1 100ms after the first pulse over the contralesional M1, during premovement stage.
Receives: Device: Dual coil transcranial magnetic stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. transcranial magnetic stimulation-evoked potential in electroencephalography (TMS-EEG)

    The amplitude of P30 (28-35ms) will be extracted from the artifact-free TEP trials to represent the cortical excitatory activity.

    Measured: Baseline

  2. Transcranial magnetic stimulation-evoked potential in electroencephalography

    The amplitude of P30 (28-35ms) will be extracted from the artifact-free TEP trials to represent the cortical excitatory activity.

    Measured: After stimulation (15 mins post)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2026
  2. Study start15 Jul 2026
  3. Primary completion31 Dec 2028 (estimated)
  4. Study completion1 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07431749
Sponsor's protocol ID
HSEARS20251026002
Status last verified
Feb 2026
First submitted
19 Feb 2026
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Dual coil transcranial magnetic stimulation in people with Cortico-cortical Paired Associative Stimulation, run by The Hong Kong Polytechnic University at 2 sites in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact JIAQI JACK Zhang, PhD (27666696, jack-jiaqi.zhang@polyu.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

transcranial magnetic stimulation-evoked potential in electroencephalography (TMS-EEG) (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in